NDC directory
Cytochrome P450 17A1 Inhibitors list
Every FDA-approved prescription drug the FDA NDC directory tags with the Cytochrome P450 17A1 Inhibitor [EPC] class, with brand names and DEA schedules.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
Map Zytiga and your other top fills to their generics
Rivvi lists each brand, its generics in RxNorm, and the brands with no generic.
Map my fillsThe FDA NDC directory lists 1 single-ingredient drug in this class: abiraterone acetate. Another 1 combination product include one of them.
Cytochrome P450 17A1 Inhibitors (2)
| Drug | Brand names | Type | NDC listings | DEA schedule |
|---|---|---|---|---|
| Abiraterone acetate | Zytiga, Yonsa | Single ingredient | 43 | Not controlled |
| Niraparib and abiraterone acetate | Akeega | Combination | 2 | Not controlled |
FDA established pharmacologic class: Cytochrome P450 17A1 Inhibitor [EPC].
Questions
What drugs are Cytochrome P450 17A1 Inhibitors?
The FDA NDC directory lists 1 single-ingredient drug in this class: abiraterone acetate. Another 1 combination product include one of them.
Where does this list come from?
From the established pharmacologic class (EPC) field FDA publishes for each listing in the NDC directory. A drug is listed when most of its prescription listings carry the class.